Blisibimod Withdrawn Phase 3 Trials for Systemic Lupus Erythematosus (SLE) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02074020CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis